FDA Risk Evaluation and Mitigation Strategies (REMS)

Random entry RSS

Posted in:
Regulatory

Biologic Patent Transparency Act Addresses High Biologic Prices
By Monica Chin Kitts May 2, 2019 Comments are off
Many factors contribute to the price that consumers pay for prescription drugs and biologics. These factors include research and...

Read more

Tagged with: AbbVie, Biologic Patent Transparency Act (BPTA), FDA, FDA Risk Evaluation and Mitigation Strategies (REMS), Humira®, Johnson & Johnson, Remicade®

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top